Pfizer announced on Wednesday to have achieved a 95% success rate on its COVID-19 vaccine development. Pfizer assures that the vaccine bears a consistent result on people of different age and ethnicity. With the announcement of the good news, Pfizer further adds plans to accelerate vaccine production.
Pfizer vaccine bears the best result among others
Pfizer vaccine is currently the vaccine with the best success rate. Reuters notes that Pfizer went through a trial involving more than 43,000 volunteers. The company further came upon 170 cases of COVID-19, in which only eight people had previously been shot with the vaccine. Pfizer further concluded the research and announced its vaccine’s efficacy rate at 95%.
Upon the update, experts have started to compare Pfizer vaccine with Moderna‘s. Moderna vaccine has not yet come up with the result of its effectivity and consistency on people of different age and ethnicity. However, Pfizer assures that its vaccines give a consistent result on different age and ethnic groups. Pfizer also mentioned that its vaccines inflicted mostly mild to moderate side effects. With the overall result, Pfizer is probably the best option available at the moment.
Quoted from Reuters, Andrew Hill of University of Liverpool’s department of pharmacology stated, “the 94% protection for older people is key. This is the evidence we needed to ensure that the most vulnerable people are protected.”
However, the distribution of Pfizer vaccines still become one of the main challenges. The vaccines require a cold temperature as cold as -70 degree Celsius as its storage. While the vaccine can still withstand in a normal fridge, it may only hold up for up to five days. Thermal shipping box may extend its longevity to around 15 days maximum.
Pfizer is up for a big plan and big aims
Despite all the challenges that Pfizer needs to go through, the company aims to accelerate the progress. According to Reuters, Pfizer and BioNTech plan to submit its research data to other regulatory agencies around the world. Both also hoping to advance the data gathered from the study to a peer-reviewed scientific journal for further research purpose. If possible, Pfizer is aiming for at least 50 million vaccine production this year, and amping it up to 1.3 billion doses in 2021.
Pfizer’s Bourla mentioned, “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world,” as quoted from Reuters.
Read also: A Trade Trigger and Its Understanding